Investors

 

Experience cutting edge cancer treatments with Isoray.

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

 

Investor Resources

Governance

Research Analyst Coverage

Ascendiant Capital Markets
Edward Woo

H.C. Wainwright & Co.
Swayampakula Ramakanth, Ph.D.

Investor News Alerts

Use the button below to email us and receive the latest investor focused news from Isoray.

Do you have questions?

We’ll put you in touch with someone to answer any of your investor related questions.

Our Management Team

 

Isoray To Launch The Power of Blu Introducing A New Brand Identity at the American Brachytherapy Society’s Annual Meeting

New Brand Identity to Be Unveiled Thursday, June 13 RICHLAND, WASHINGTON – June 12, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology...

Isoray Announces Record Third Quarter Fiscal 2019 Financial Results

Record Revenue and Gross Profit Revenue Increased 22% Year-Over-Year RICHLAND, WASHINGTON – May 9, 2019 -- Isoray, Inc. (NYSE AMERICAN: ISR), a...

Isoray To Announce Third Quarter Fiscal 2019 Financial Results on May 9, 2019

Conference Call is May 9 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – May 1, 2019 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology...

Isoray Collaborates With Texas Oncology to Fill Void in Training Programs For Next Generation of Brachytherapists

RICHLAND, WASHINGTON – April 16, 2019 – Isoray, Inc. (NYSE American: ISR), a medical technology company and innovator in brachytherapy powering...

Webinar: Transitioning Isotopes for Prostate Brachytherapy – April 17th, 2019

After nearly 10 years and more than 12,000 patients treated following its FDA approval for prostate cancer treatment, sufficient scientific data and...